Isis maintained by Stanford Group at buy

Isis Pharmaceuticals Inc. was maintained by Stanford Group Co. analysts Dallas Webb and Aaron Reames at a buy rating with a price target on the stock of $8 per share following the first shipment of its Tiger biosensor systems to the U.S. Army Medical Research Institute for Infectious Disease. Isis shares Friday climbed $0.28, or 5.21%, to close at $5.65 on volume of 1,705,622 shares versus the three-month running average of 440,942 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.